And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

Shalini Sharp Biography and Net Worth

Director of Neurocrine Biosciences

Shalini Sharp has served on the Board of Directors since February 2020. She also serves on the Board of Directors of Organon & Co., a publicly traded healthcare company focused on improving the health of women throughout their lives. Previously, Ms. Sharp served on the Board of Directors of Mirati Therapeutics, prior to its acquisition by Bristol-Myers Squibb Company, Sutro Biopharma, Inc., Panacea Acquisition Corp., prior to its merger with Nuvation Bio, Precision BioSciences, Inc., TB Alliance, Array Biopharma, prior to its acquisition by Pfizer, and Agenus Inc. Ms. Sharp has held the positions of Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus Inc., a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. Ms. Sharp previously served in strategic planning and as Chief of Staff to the Chairman of the Board of Directors of Elan Pharmaceuticals, and as a management consultant at McKinsey & Company, as well as an investment banker at Goldman Sachs. She holds a B.A. and an M.B.A. from Harvard University.

What is Shalini Sharp's net worth?: The estimated net worth of Shalini Sharp is at least $138,245.52 as of May 17th, 2024. Ms. Sharp owns 994 shares of Neurocrine Biosciences stock worth more than $138,246 as of July 6th. This net worth evaluation does not reflect any other investments that Ms. Sharp may own. Learn More about Shalini Sharp's net worth.
How do I contact Shalini Sharp?: The corporate mailing address for Ms. Sharp and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Shalini Sharp's contact information.
Has Shalini Sharp been buying or selling shares of Neurocrine Biosciences?: Shalini Sharp has not been actively trading shares of Neurocrine Biosciences during the past quarter. Most recently, Shalini Sharp sold 1,106 shares of the business's stock in a transaction on Friday, May 17th. The shares were sold at an average price of $141.90, for a transaction totalling $156,941.40. Following the completion of the sale, the director now directly owns 994 shares of the company's stock, valued at $141,048.60. Learn More on Shalini Sharp's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 49 times. They sold a total of 562,140 shares worth more than $74,219,148.22. The most recent insider tranaction occured on July, 1st when insider Julie Cooke sold 10,000 shares worth more than $1,401,900.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 7/1/2024.

Shalini Sharp Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/17/2024	Sell	1,106	$141.90	$156,941.40	994

Shalini Sharp Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $139.08

$135.85

$139.72

50 Day Range

MA: $137.48

$130.86

$143.19

2 Week Range

Now: $139.08

$93.28

$148.37

Volume

445,245 shs

Average Volume

730,587 shs

Market Capitalization

$14.00 billion

P/E Ratio

38.31

Dividend Yield

N/A

Beta

0.37

Grab Your Free Bitcoin Today!

From Crypto Swap Profits | Ad

>> Register right here